Amneal Pharmaceuticals, Inc. AMRX Affordable Medicines — Operating Income (Loss)
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s affordable medicines — operating income (loss).
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s affordable medicines — operating income (loss)?
- Amneal Pharmaceuticals, Inc. (AMRX) reported affordable medicines — operating income (loss) of $120.94M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s affordable medicines — operating income (loss) changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s affordable medicines — operating income (loss) increased by 9.2% year-over-year, from $110.79M to $120.94M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s affordable medicines — operating income (loss)?
- Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s affordable medicines — operating income (loss) has grown at a 19.3% compound annual growth rate (CAGR), from $224.16M to $380.8M.
- What does affordable medicines — operating income (loss) mean?
- Measures the profitability of the segment after deducting operating expenses from net revenue. It serves as a primary indicator of the segment's ability to generate value from its core pharmaceutical business activities.